Clinical Trial Update: Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update examining how Advagraf de Novo tacrolimus dosing after kidney transplantation may be tailored by recipient genetic polymorphism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Advagraf de Novo (Tacrolimus)

Snippet

Sponsor: Université Catholique de Louvain | Conditions: Kidney Diseases | Phase 4 | Status: UNKNOWN